On Monday, Exelixis stock hit an important technical milestone, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an improvement to 87, an increase from 79 the day before.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Exelixis Stock A Buy?
Exelixis stock has moved more than 5% past a 20.56 entry in a first-stage flat base, meaning it's now extended and out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings growth rose last quarter from -38% to 11%. But sales fell from 15% to 12%.
Exelixis stock earns the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. Kiniksa Pharmaceuticals and Catalyst Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
